What is primary effusion lymphoma?
Primary effusion lymphoma (PEL) is a rare, aggressive type of B-cell non-Hodgkin lymphoma. Unlike most lymphomas, it does not usually form a lump or enlarge the lymph nodes. Instead, the lymphoma cells grow in fluid that collects in the body’s cavities.
The cavities most often affected are the space around the lungs (pleural cavity), the abdomen (peritoneal cavity) and the sac around the heart (pericardium). A build-up of fluid in one of these spaces is called an effusion, which gives the disease its name.
PEL is always linked with a virus called Kaposi sarcoma herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8). It was first recognised in the mid-1990s in people with AIDS, when researchers found KSHV in lymphomas growing in body cavities (Cesarman et al., 1995; Nador et al., 1996).
Most people with PEL have HIV infection with a weakened immune system. A smaller number are older people without HIV, or people taking immune-suppressing medicines after an organ transplant.
The World Health Organization places PEL among the KSHV/HHV-8-associated B-cell lymphoid proliferations and lymphomas (Alaggio et al., 2022).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of disease | Aggressive large B-cell lymphoma linked with KSHV/HHV-8 |
| How common | Very rare; about 4% of HIV-associated lymphomas and under 1% of all lymphomas |
| Who is affected | Mainly men living with HIV; also older people without HIV and transplant recipients |
| Main sites | Fluid around the lungs, in the abdomen or around the heart |
| Key symptoms | Breathlessness, swollen abdomen, fever, night sweats, weight loss |
| Other viruses | Epstein-Barr virus (EBV) is also present in most HIV-related cases |
| Main treatment | Antiretroviral therapy plus combination chemotherapy |
| Outlook | Serious; median survival about 1-2 years, but some people achieve long remissions |
2. Types of primary effusion lymphoma
| Type | Description |
|---|---|
| Classic PEL | Lymphoma cells are found in fluid in one or more body cavities, with no solid mass |
| Extracavitary PEL | A solid tumour, often in the gut, skin, lung or lymph nodes, made of the same cells and carrying KSHV |
| EBV-positive PEL | Most HIV-related cases; the cells also contain Epstein-Barr virus |
| EBV-negative PEL | More common in older people without HIV |
Extracavitary PEL behaves in a similar way to classic PEL. Some people have both a mass and an effusion, or develop an effusion later (Guillet et al., 2016).
3. Causes and risk factors
The role of KSHV/HHV-8
KSHV is a herpesvirus that infects some B cells and stays in them for life. In most healthy people, the immune system keeps the virus under control. When immunity is weak, infected B cells can grow out of control and become lymphoma.
The virus carries genes that help infected cells survive and divide, including copies of human cell-cycle and signalling genes (Cesarman et al., 1996). KSHV is also the cause of Kaposi sarcoma and of a type of multicentric Castleman disease (MCD).
Who is at risk?
| Risk factor | Explanation |
|---|---|
| HIV infection | The main risk factor, especially with a low CD4 count or uncontrolled virus |
| Previous Kaposi sarcoma | Many people with PEL have, or have had, Kaposi sarcoma |
| KSHV-associated multicentric Castleman disease | Can occur before, with or after PEL |
| Organ transplantation | Immune-suppressing medicines reduce control of KSHV |
| Older age in areas where KSHV is common | For example the Mediterranean region and parts of Africa |
| Male sex | Most patients are men |
How is KSHV spread?
KSHV is mostly spread through saliva. It can also pass through sexual contact, blood and organ transplants. The virus is far more common in some parts of the world, such as sub-Saharan Africa and the Mediterranean, than in northern Europe or North America.
Being infected with KSHV does not mean someone will develop PEL. The lymphoma is very rare even among people who carry the virus.
PEL itself is not contagious. It cannot be caught from someone who has it.
4. How does it look
On scans
| Feature | What doctors see |
|---|---|
| Effusion | Fluid around one or both lungs, in the abdomen (ascites) or around the heart |
| No large mass | Typically no solid tumour and no large lymph nodes in classic PEL |
| Thickened lining | The lining of the chest or abdomen may look slightly thickened |
| Extracavitary PEL | A solid mass, for example in the bowel wall, skin or lymph nodes |
| PET-CT | The cavity lining and fluid may take up the tracer, showing active disease |
A chest X-ray or CT scan often shows a pleural effusion. An ultrasound or echocardiogram can show fluid in the abdomen or around the heart.
The fluid
When doctors drain the fluid, it may look cloudy, yellow or blood-stained. Under the microscope, the fluid contains many large abnormal lymphocytes.
Under the microscope
| Feature | Description |
|---|---|
| Cell size | Large cells with big nuclei and prominent nucleoli |
| Appearance | Ranges from immunoblastic and plasmablastic to anaplastic |
| Usual B-cell markers | Often absent: CD19, CD20 and CD79a are usually negative |
| Markers present | CD45, CD30, CD38, CD138 and MUM1/IRF4 |
| KSHV marker | LANA-1 (HHV-8 latency-associated nuclear antigen) is positive in all cases and is essential for the diagnosis |
| EBV | EBV-encoded RNA (EBER) is positive in most HIV-related cases |
Because PEL cells lack the usual B-cell markers, the diagnosis can be difficult. Proving the presence of KSHV in the cells is the key step (Narkhede, Arora and Ujjani, 2018).
Visible signs
Others may notice a swollen abdomen, breathlessness on mild effort or weight loss. People who also have Kaposi sarcoma may have purple or brown patches on the skin or in the mouth.
5. Symptoms
Symptoms depend on which cavity is affected and how much fluid has built up.
Fluid around the lungs
- Breathlessness, which gets worse over days or weeks
- Dry cough
- Chest discomfort or a feeling of tightness
- Needing to sleep propped up
Fluid in the abdomen
- Swelling of the abdomen and weight gain from fluid
- Feeling full quickly after eating
- Abdominal discomfort
- Nausea and loss of appetite
Fluid around the heart
- Breathlessness, especially when lying flat
- Fast heartbeat and dizziness
- Swollen legs
- In severe cases, a dangerous drop in blood pressure (cardiac tamponade), which is an emergency
General symptoms
| Symptom | Notes |
|---|---|
| Fever | Often without infection |
| Drenching night sweats | Known as a “B symptom” |
| Weight loss | More than 10% of body weight in six months |
| Tiredness | Common and often severe |
KSHV inflammatory cytokine syndrome (KICS)
Some people develop KICS, a condition in which KSHV drives very high levels of inflammatory signals such as interleukin-6. It causes high fevers, low blood counts, swelling and low blood pressure, and needs urgent treatment.
When to seek medical advice
See a doctor promptly for breathlessness that is getting worse, a swelling abdomen, or ongoing fever and night sweats, especially if you live with HIV.
Seek emergency help for severe breathlessness, chest pain or fainting.
6. Diagnosis
| Test | Purpose |
|---|---|
| Chest X-ray, ultrasound and CT | Show where fluid has collected |
| Drainage of the fluid | Relieves symptoms and provides cells for testing |
| Cytology and flow cytometry | Identify large abnormal lymphocytes |
| Immunohistochemistry | Shows CD30, CD138 and MUM1, and confirms LANA-1 positivity |
| EBV testing (EBER) | Checks for Epstein-Barr virus in the cells |
| Biopsy | Needed for extracavitary PEL or a thickened lining |
| PET-CT | Shows the extent of disease |
| HIV test, CD4 count and HIV viral load | Essential for every patient |
| KSHV viral load in blood | Helps to assess disease activity and KICS |
| Blood tests | Blood count, kidney and liver function, LDH, IL-6 and CRP |
| Bone marrow tests | Sometimes done if blood counts are low |
Conditions that can look similar
| Condition | How it differs |
|---|---|
| Pleural effusion from infection or heart failure | No lymphoma cells in the fluid |
| Pleural mesothelioma | A tumour of the lining cells, not lymphocytes |
| Plasmablastic lymphoma | Similar cells, but KSHV-negative |
| Diffuse large B-cell lymphoma with an effusion | Usually CD20-positive and KSHV-negative |
| Fluid overload-associated large B-cell lymphoma | KSHV-negative; usually older people with heart, liver or kidney disease and a better outlook |
7. Treatment
PEL is treated at a specialist lymphoma centre, ideally with an HIV specialist working alongside the haematology team. There is no single agreed standard, because the disease is so rare (Narkhede, Arora and Ujjani, 2018).
Main treatment parts
| Treatment | Role |
|---|---|
| Antiretroviral therapy (ART) | Started or continued in everyone with HIV; restores immunity and improves survival |
| Combination chemotherapy | CHOP or dose-adjusted EPOCH; given in cycles over several months |
| Drainage of fluid | Repeated drainage or a long-term drain to ease breathlessness or swelling |
| Infection prevention | Antibiotics and antivirals to prevent infections such as pneumocystis pneumonia |
| Reducing immune suppression | In transplant recipients, if possible |
Chemotherapy
CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) and dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin) are the most commonly used regimens.
Rituximab usually adds little, because PEL cells normally lack CD20. It may be used when PEL occurs together with KSHV-associated multicentric Castleman disease or in rare CD20-positive cases.
Treatment of relapsed or resistant disease
| Option | Notes |
|---|---|
| Further chemotherapy | Different drug combinations |
| High-dose chemotherapy with autologous stem cell transplant | For selected people who respond well |
| Brentuximab vedotin | Targets CD30, which PEL cells often carry; used in trials or off-label |
| Pomalidomide or lenalidomide | Immune-modulating drugs studied in KSHV-associated diseases (Lurain et al., 2021) |
| Daratumumab | Targets CD38; activity has been reported in refractory PEL (Shrestha et al., 2023) |
| Clinical trials | Strongly encouraged |
Side effects of treatment
| Side effect | Notes |
|---|---|
| Low blood counts and infections | The main risk, especially with HIV |
| Hair loss | Usually temporary |
| Nausea and tiredness | Controlled with supportive medicines |
| Tingling in hands and feet | From vincristine |
| Drug interactions | Some HIV medicines interact with chemotherapy, so regimens are planned together |
8. Outlook (prognosis)
PEL has historically had a poor outlook, with median survival of around 6 months in the early years after it was first described. Results have improved with effective antiretroviral therapy and modern chemotherapy.
| Factor | Effect on outlook |
|---|---|
| Good performance status | Better outlook (Boulanger et al., 2005) |
| Taking effective ART | Better outlook |
| Only one cavity involved | Better outlook |
| Complete response to chemotherapy | Better outlook; some people stay in remission for years |
| Several cavities involved | Poorer outlook |
| KICS or multicentric Castleman disease | Poorer outlook |
In a French study of 51 people with HIV, the median survival was about 10 months. People who reached complete remission did much better (Guillet et al., 2016).
In a later study from the US National Cancer Institute, median survival was about 22 months. Survival levelled off after about two years, meaning that people who were well at that point often stayed in remission for a long time (Lurain et al., 2019). Treatment with the aim of long-term control is therefore offered to everyone who is fit enough.
9. Prevention
There is no vaccine against KSHV. The best ways to lower the risk of PEL are:
- Testing for HIV and starting antiretroviral therapy early
- Taking HIV medicines every day to keep the virus suppressed and the CD4 count healthy
- Safer sex and not sharing needles
- Careful monitoring of transplant recipients who carry KSHV
10. Living with primary effusion lymphoma
- Take HIV medicines exactly as prescribed, including during chemotherapy
- Report fever promptly, as infections can become serious quickly
- Ask about a long-term drain if fluid keeps coming back
- Eat well and stay active as much as possible
- Seek emotional support; HIV and lymphoma charities offer advice and peer support
- Keep a list of all medicines to help avoid drug interactions
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is PEL the same as Kaposi sarcoma? | No. Both are caused by KSHV, but PEL is a lymphoma and Kaposi sarcoma is a tumour of blood vessel cells |
| Can people without HIV get PEL? | Yes, mainly older people in areas where KSHV is common and transplant recipients |
| Can PEL be cured? | Some people achieve long-lasting remission, especially with ART and a complete response to chemotherapy |
| Why does the fluid come back? | Lymphoma cells keep producing fluid until the lymphoma is controlled |
| Will I need to stop my HIV medicines? | No. ART is continued; the team may change some drugs to avoid interactions |
| Is PEL inherited? | No |
12. Questions to ask your care team
- Is the lymphoma classic or extracavitary PEL?
- Which cavities are affected?
- What chemotherapy do you recommend and why?
- How will my HIV treatment be managed during chemotherapy?
- Do I have signs of KICS, Kaposi sarcoma or Castleman disease?
- What can be done if the fluid keeps coming back?
- Are there clinical trials I could join?
Resources
- Alaggio, R. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms’, Leukemia, 36(7), pp. 1720-1748.
- Boulanger, E. et al. (2005) ‘Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS’, Journal of Clinical Oncology, 23(19), pp. 4372-4380.
- Cesarman, E. et al. (1995) ‘Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas’, New England Journal of Medicine, 332(18), pp. 1186-1191.
- Cesarman, E. et al. (1996) ‘Kaposi’s sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi’s sarcoma and malignant lymphoma’, Journal of Virology, 70(11), pp. 8218-8223.
- Guillet, S. et al. (2016) ‘Classic and extracavitary primary effusion lymphoma in 51 HIV-infected patients from a single institution’, American Journal of Hematology, 91(2), pp. 233-237.
- Lurain, K. et al. (2019) ‘Viral, immunologic, and clinical features of primary effusion lymphoma’, Blood, 133(16), pp. 1753-1761.
- Lurain, K. et al. (2021) ‘Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma’, Journal for ImmunoTherapy of Cancer, 9(2), e002097.
- Nador, R.G. et al. (1996) ‘Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus’, Blood, 88(2), pp. 645-656.
- Narkhede, M., Arora, S. and Ujjani, C. (2018) ‘Primary effusion lymphoma: current perspectives’, OncoTargets and Therapy, 11, pp. 3747-3754.
- Shrestha, P. et al. (2023) ‘Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease’, OncoImmunology, 12(1), 2163784.
- National Cancer Institute (2026) AIDS-Related Lymphoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lymphoma/hp/aids-related-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.